These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 25392091)

  • 21. Effect of VEGF on neuronal degeneration and interaction between Alzheimer's disease biomarkers.
    Yuan HC; Jiang CW; Hou LY; Lv YB; Feng XZ; Guo LF; Sun G; Liu K; Liu YJ; Xu B; Wang CY
    Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):3982. PubMed ID: 29028108
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retraction: Association between bevacizumab-related chemotherapy regimens and serum vascular endothelial growth factor-A165b level in patients with metastatic colorectal cancer.
    Xu L; Chi C; Wang C; Zhang LM
    Eur Rev Med Pharmacol Sci; 2014 Oct; 18(20):2982. PubMed ID: 25392091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bevacizumab plus irinotecan-based regimens in the treatment of metastatic colorectal cancer.
    Heinemann V; Hoff PM
    Oncology; 2010; 79(1-2):118-28. PubMed ID: 21088438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
    Wagner AD; Thomssen C; Haerting J; Unverzagt S
    Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
    Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
    Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer.
    Chase JL
    Pharmacotherapy; 2008 Nov; 28(11 Pt 2):23S-30S. PubMed ID: 18980549
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intermediate filament Nestin and the cell motility in cancer - a review.
    Shi AM; Tao ZQ; Wang X; Wang YQ
    Eur Rev Med Pharmacol Sci; 2016 Sep; 20(17):3514. PubMed ID: 27649646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integration of novel agents in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer.
    Hochster HS
    Semin Oncol; 2006 Oct; 33(5 Suppl 10):S8-14. PubMed ID: 17145525
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer.
    Loupakis F; Stein A; Ychou M; Hermann F; Salud A; Österlund P
    Target Oncol; 2016 Jun; 11(3):293-308. PubMed ID: 26687849
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-angiogenic therapies for metastatic colorectal cancer.
    Wagner AD; Arnold D; Grothey AA; Haerting J; Unverzagt S
    Cochrane Database Syst Rev; 2009 Jul; (3):CD005392. PubMed ID: 19588372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
    Shih T; Lindley C
    Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.
    Venook AP
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S74-84. PubMed ID: 19780248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prevalent KRAS exon 2 c.35 G>A mutation in metastatic colorectal cancer patients: A biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens?
    Bruera G; Cannita K; Tessitore A; Russo A; Alesse E; Ficorella C; Ricevuto E
    Crit Rev Oncol Hematol; 2015 Mar; 93(3):190-202. PubMed ID: 25459669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High VEGF-A level at baseline predicts poor treatment effect of bevacizumab-based chemotherapy in metastatic colorectal cancer: a meta-analysis.
    Zhao L; Zhang D; Ma H; Jin M; Huang F; Zhang T
    Panminerva Med; 2016 Mar; 58(1):48-58. PubMed ID: 26763741
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bevacizumab and oxaliplatin-based chemotherapy in metastatic colorectal cancer.
    Beatty GL; Giantonio BJ
    Expert Rev Anticancer Ther; 2008 May; 8(5):683-8. PubMed ID: 18471041
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
    Tol J; Punt CJ
    Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of targeted therapy in the treatment of colorectal cancer.
    Goldberg RM; Hurwitz HI; Fuchs CS
    Clin Adv Hematol Oncol; 2006 Aug; 4(8 Suppl 17):1-10; quiz 11-2. PubMed ID: 17139241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer.
    de Gramont A; Van Cutsem E
    Oncology; 2005; 69 Suppl 3():46-56. PubMed ID: 16301835
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New Trends in the Therapeutic Approach to Metastatic Colorectal Cancer.
    Sánchez-Gundín J; Fernández-Carballido AM; Martínez-Valdivieso L; Barreda-Hernández D; Torres-Suárez AI
    Int J Med Sci; 2018; 15(7):659-665. PubMed ID: 29910669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.